Terug naar eerste hoofdstuk

 

Referenties

  • Aaby, P., et al., Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age. BMJ, 1993. 307(6915): p. 1308-11 (link)
  • Bautista-Lopez, N., et al., Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine, 2000. 18(14): p. 1393-401 (link)
  • Block, S.L., et al., Immunogenicity and Safety of a 3- and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants: Results of a Phase 3b, Randomized, Open-label Trial. Pediatr Infect Dis J, 2016. 35(2): p. e48-59 (link)
  • Bont de EGPM, Brand PLP, Dinant GJ. Wel of geen paracetamol bij kinderen met koorts? NedTijdschr Geneeskunde 2014,158:A6636 (link)
  • Borja-Tabora, C.F., et al., Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial. BMC Infect Dis, 2015. 15: p. 409 (link)
  • Buijs SC & Boersma B. Cardiorespiratoire verstoringen na 1e vaccinatie bij prematuur geboren kinderen, een prospectief cohortonderzoek. Nederlands Tijdschrift voor Geneeskunde 2012, 156:3797 (link)
  • Burgmeijer R, Hoppenbrouwers K, van Gompel F. Handboek vaccinaties: Deel A en B, Van Gorcum, 2de herziene druk 2011
  • Chen RT, Clark TA, Halperin SA. The yin and yang of Paracetamol and paediatric immunizations. Lancet 2009, 374:1305-06 (link)
  • Clifford V, Crawford NW, Royle J, et al. Recurrent apnoea post immunisation: Informing re-immunisation policy. Vaccine 2011;29:5681-7 (link)
  • de Greeff SC1, Mooi FR, Westerhof A, Verbakel JM, Peeters MF, Heuvelman CJ, Notermans DW, Elvers LH, Schellekens JF, de Melker HE, Pertussis disease burden in the household: how to protect young infants.Clin Infect Dis. 2010 May 15;50(10):1339-45 doi: 10.1086/652281 (link)
  • De Groot 2014 Handhygiëne in de jeugdgezondheidszorg, ook bij het vaccineren? Infectieziekten Bulletin Maart 2014 (link)
  • De Serres, G., et al., Effectiveness of vaccination at 6 to 11 months of age during an outbreak of measles. Pediatrics, 1996. 97(2): p. 232-5. (link)
  • De Serres, G., et al., Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12-14 months versus 15 months of age. Clin Infect Dis, 2012. 55(3): p. 394-402 (link)
  • De Serres, G., et al., Largest measles epidemic in North America in a decade--Quebec, Canada, 2011: contribution of susceptibility, serendipity, and superspreading events. J Infect Dis, 2013. 207(6): p. 990-8. (link)
  • Doedée AM, Boland GJ, Pennings JL, de Klerk A, Berbers GA, van der Klis FR, de Melker HE, van Loveren H, Janssen R. Effects of prophylactic and therapeutic paracetamol treatment during vaccination on hepatitis B antibody levels in adults: two open-label, randomized controlled trials. PLoS One. 2014 Jun 4;9(6):e98175 (link)
  • Flatz-Jequier A, Posfay-Barbe KM, Pfister RE, Siegrist CA. Recurrence of cardiorespiratory events following repeat DTaP-based combined immunization in very low birth weight premature infants. The Journal of pediatrics 2008;153:429-31 (link)
  • Furck AK, Richter JW, Kattner E. Very low birth weight infants have only few adverse events after timely immunization. Journal of perinatology 2010, 30:118-121 Heath 2012) (pdf)
  • Gans, H., et al., Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis, 2001. 184(7): p. 817-26. (link)
  • Gans, H., et al., Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine, 2003. 21(24): p. 3398-405. (link)
  • Gans, H.A., et al., Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA, 1998. 280(6): p. 527-32. (link)
  • Gans, H.A., et al., Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age. J Infect Dis, 2013. 207(4): p. 574-82 (link)
  • Gezondheidsraad 2007 De toekomst van het Rijksvaccinatieprogramma (link)
  • Gezondheidsraad 2008 Vaccinatie tegen baarmoederhalskanker (link)
  • Gezondheidsraad 2009 Algemene vaccinatie tegen hepatitis B herbeoordeeld (link)
  • Gezondheidsraad 2010 Vaccinatie van zuigelingen tegen pneumokokkeninfecties (link)
  • Gezondheidsraad 2012 Het Rijksvaccinatieprogramma in Caribisch Nederland (link)
  • Gezondheidsraad 2013 Vaccinatie van zuigelingen tegen pneumokokkeninfecties (link)
  • Gezondheidsraad 2015 Vaccinatie tegen kinkhoest: doel en strategie (link)
  • Gill, C.J., et al., Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo) or Menactra among healthy adolescents. Hum Vaccin, 2010. 6(11): p. 881-7. (link)
  • Hilgersom JA, AAWAlgemene arbeidsongeschiktheidswet. van Boekel, HC Rümke. Aanvallen na vaccinatie van zuigelingen en peuters’. Tijdschr Jeugdgezondheidsz (2017) 49:2–7 DOI 10.1007/s12452-016-0092-4 Januari 2017 (link)
  • Hutchins, S.S., et al., Evaluation of an early two-dose measles vaccination schedule. Am J Epidemiol, 2001. 154 (11): p. 1064-71 (pdf)
  • Hutin van Y, Anja Hauri, Linda Chiarello, Mary Catlin, Barbara Stilwell, Tesfamicael Ghebrehiwet, Julia Garner, & the Members of the Injection Safety Best Practices Development Group Objective Best infection control practices for intradermal, subcutaneous, and intramuscular needle injections 2003 (pdf)
  • Johnston, W., et al., Comparative Assessment of a Single Dose and a 2-dose Vaccination Series of a Quadrivalent Meningococcal CRM-conjugate Vaccine (MenACWY-CRM) in Children 2-10 Years of Age. Pediatr Infect Dis J, 2016. 35(1): p. e19-27 (link)
  • Julsgaard, M, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology 2016;151: 110-9. (link)
  • Kaninda AV et al., Measles vaccine effectiveness in standard and early immunization strategies, Niger, 1995 (link)
  • Kemmeren JM, de Melker HE, The National Immunisation Programme in the Netherlands. Developments in 2009 Het Rijksvaccinatieprogramma in Nederland. Ontwikkelingen in 2009 18-05-2010 (link)
  • King AJ, van Gorkom T, van der Heide HG, Advani A, van der Lee S. Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift? BMC Genomics. 2010 Jan 26;11:64. (link)
  • Klein, N.P., et al., Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children. Pediatr Infect Dis J, 2016. 35(6): p. 662-72. (link)
  • Knuf, M., et al., A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine  administered in the second year of life and in young children. Vaccine, 2010. 28(3): p. 744-53. (link)
  • Lafeber Prospectief Vaccinatie Onderzoek. Antistofrespons bij kinderen in het Rijksvaccinatieprogramma Eindrapportage. 2002 (link)
  • Lalwani, S., et al., Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years. Int J Infect Dis, 2015. 38: p. 36-42. (link)
  • Ling, J, Koren G, Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Rev Vaccines 2016;15(2): 239-56. (link)
  • Mahadevan, U, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11(3): 286-92. (link)
  • Mahieu L. Vaccinatie van prematuur geboren kinderen. Vlaams Infectieziekten bulletin 2009 pag 11-16 (pdf)
  • Markowitz, L.E., et al., Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N Engl J Med, 1990. 322(9): p. 580-7 (link)
  • Markowitz, L.E., et al., Persistence of measles antibody after revaccination. J Infect Dis, 1992. 166(1): p. 205 (link)
  • Meinus C, Schmalisch G, Hartenstein S, Proquitté H, Roehr CC. Adverse cardiorespiratory events following primary vaccination of very low birth weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-doi:10.2223/JPED.2182. (link)
  • Mialet-Marty T, Beuchee A, Ben Jmaa W, et al. Possible predictors of cardiorespiratory events after immunization in preterm neonates. Neonatology 2013;104:151-5 (link)
  • Murphy, M.D., et al., Effect of early immunization on antibody response to reimmunization with measles vaccine as demonstrated by enzyme-linked immunosorbent assay (ELISA). Pediatrics, 1984. 74(1): p. 90-3. (link).
  • Naleway AL, Kurosky S, Henninger ML, Gold R, Nordin JD, Kharbanda EO, Irving S, Craig Cheetham T, Nakasato C, Glanz JM, Hambidge SJ, Davis RL, Klein NP, McCarthy NL, Weintraub Vaccinations given during pregnancy 2002-2009: a descriptive study. Am J Prev Med. 2014 Feb;46(2):150-7 (link)
  • Plotkin S, Orenstein W, Offit P, Edwards KM, Plotkin's Vaccines 7th edition 2017
  • Porter, J.D., et al., Measles outbreaks in the Mozambican refugee camps in Malawi: the continued need for an effective vaccine. Int J Epidemiol, 1990. 19(4): p. 1072-7 (link)
  • Prymula R, Esposito S, Zuccotti GV, Xie F, Toneatto D, Kohl I, Dull PM Phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I) Effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB 2014 Human Vaccines & Immunotherapeutics Volume 10, 2014 - Issue 7 (link)
  • Prymula R, Siegrist C, Chlibek R et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label randomised controlled trials. Lancet 2009, 374:1339–50 (link)
  • Puthanakit T., Schwarz T., Esposito S., Frenette L., McNeil S., Rheault P.6 Horn M., Poncelet S., Suryakiran P., Hezareh M., Thomas F., Descamps D., Struyf F. Immune responses to a 2-dose schedule of the HPV-16/18 as04-adjuvanted vaccine in girls (9-14) versus 3 doses in women (15-25): a randomised trial Chulalongkorn University, Faculty of Medicine, Department of Pediatrics, Division of Infectious Diseases, Bangkok 2013 (link)
  • Rashmi, Panigrahi, Naik Effect of Prophylactic Antipyretic Administration on Post-Vaccination Adverse Reactions and Antibody Response in Children: A Systematic Review sept 2014 in Human Vaccines & Immunotherapeutics juli 2014 (pdf)
  • Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Suryakiran P, Thomas F, Struyf F Immune response to the HPV-16/18 as04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination 2013 (link)
  • Rümke HC Postvaccinatie verschijnselen: prikplaatsreacties en reactogeniciteit Tijdschr Jeugdgezondheidsz (2016) 48 :50–56 DOI 10.1007/s12452-016-0060-z. Mei 2016. (link)
  • Rümke HC, Kant AC. RVPRijksvaccinatieprogramma-vaccinaties: melden van bijwerkingen. Tijdschr Jeugdgezondheidsz (2014) jaargang 46 nr 4: 75-80 (link)
  • Rümke HC. Samenstelling van vaccins en bijwerkingen Tijdschr Jeugdgezondheidsz (2016): 1-8 DOI 10.1007/ s12452-016-0087-1. 11-11-2016 (link)
  • Shasby, DM. et al., Epidemic measles in a highly vaccinated population. N Engl J Med, 1977.296(11):p. 585-9. (link)
  • Skibinski DAG, Baudner BC, Singhet M et al. Combination Vaccines. J Glob Infect Dis 2011, 3:63-72 (link)
  • Snape, M.D., et al., Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA, 2008. 299(2): p. 173-84. (link)
  • Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, Elberse KE, van Gageldonk PG, Knol MJ, de Melker HE, Sanders EA, Schouls LM, Berbers GA. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial. JAMA. 2013 Sep 4;310(9):930-7. doi: 10.1001/jama.2013.228052 (link)
  • Stetler, H.C., et al., Impact of revaccinating children who initially received measles vaccine before 10 months of age. Pediatrics, 1986. 77(4): p. 471-6. (link)
  • Taddio A , Wong H, Welkovics B , Ilersich AL, Cole M, Goldbach M , Ipp M A randomized trial of the effect of vaccine injection speed on acute pain in infants Vaccine 34 ( 2016) : 4672 – 4677 (link)
  • Vermeer PE, Moorer-Lanser N, Phaff TAJ et al. Adverse Events in the Netherlands Vaccination Programme. Reports in 2010 and Review 1994-2010. RIVMRijksinstituut voor Volksgezondheid en Milieu 2012 (link)
  • Vesikari, T., et al., Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines. Pediatr Infect Dis J, 2015. 34(12): p. e298-307. (link)
  • Vreeswijk van, Bos-Veneman, Reijneveld Pijnreductie bij vaccinatie van jonge kinderen Ned Tijdschr Geneeskd. 2017;161:D1405 (link)
  • Whelan J, Hahné S, Guy A.M. Berbers, Fiona van der Klis, Yvonne Wijnands & Hein Boot, Human Vaccines & Immunotherapeutics ISSN: 2164-5515 Immunogenicity of a hexavalent vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Findings from the National Immunisation Programme in the Netherlands (link)
  • WHO Renewed commitment to elimination of measles and rubella and prevention of congenital rubella syndrome by 2015 and Sustained support for polio-free status in the WHO European Region 2010 (pdf)
  • Wieringa JW, Driessen GJ, van der Woude CJ. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system. Expert Rev Gastroenterology & Hepatology 2018;12(8):811-8. (link)
  • Wijhe, Maarten van, Melker Hester de, Postma Maarten, Wallinga Jacco, Effect of vaccination programmes on mortality burden among children and young adults in the Netherlands during the 20th century: a historical analysis 09 February 2016 The Lancet (link)
  • Wilkins, J. and P.F. Wehrle, Additional evidence against measles vaccine administration to infants less than 12 months of age: altered immune response following active/passive immunization. J Pediatr, 1979. 94(6): p. 865-9. (link)
  • Zhao J, Gonzalez F, Mu D.Apnea of prematurity: from cause to treatment. EurErasmus Universiteit Rotterdam.J.Pediatr. 2011;170(9): 1097-105 (link

Websites van betrokken organisaties

Afkortingen

Actiz

Branchevereniging organisaties die actief zijn op het gebied van zorg en ondersteuning aan ouderen, (chronisch) zieken en jeugd

AEFI

Adverse event following immunisation

AJN

Jeugdartsen Nederland

Amvb

Algemene maatregel van bestuur

BCG

Bacillus Calmette–Guérin (vaccin tegen tuberculose)

BMRBof, mazelen, rodehond

Bof, mazelen en rodehond

BRP

Basis Registratie Personen

BSNBurger Service Nummer

Burgerservicenummer

CIbCentrum Infectieziektebestrijding (onderdeel van het RIVM)

Centrum Infectieziektebestrijding (onderdeel van het RIVMRijksinstituut voor Volksgezondheid en Milieu)

CJG

Centrum voor Jeugd en Gezin

COA

Centraal Orgaan Opvang Asielzoekers

DD JGZJeugdgezondheidszorg

Digitaal Dossier Jeugdgezondheidszorg

DKTPDifterie, kinkhoest, tetanus, polio

Difterie, kinkhoest, tetanus en poliomyelitis

DKTP-Hib-HepB

Difterie, kinkhoest, tetanus, poliomyelitis, Hib-ziekten en hepatitis B

DTPDifterie, Tetanus en Poliomyelitis

Difterie, tetanus en poliomyelitis

DVP

Dienst Vaccinvoorziening en Preventieprogramma's (onderdeel van het RIVM)

ECDCEuropean Centre for Disease Prevention and Control

European Centre for Disease Prevention and Control

GGDGemeentelijke/gewestelijke gezondheidsdienst

Gemeentelijke of Gemeenschappelijke Gezondheidsdienst

GGD GHORGeneeskundige Hulpverleningsorganisatie in de Regio NL

Koepelorganisatie van de 25 GGD'en en GHOR-bureaus

GHOR

Geneeskundige Hulpverleningsorganisatie in de Regio

HBsAg

Hepatitis B surface antigeen

HepB

Hepatitis B

Hib

Haemophilus influenzae type b

HPV

Humaan papillomavirus

Ig

Immunoglobuline

IGJ

Inspectie Gezondheidszorg en Jeugd (voorheen Inspectie voor de Gezondheidszorg)

IPV

Inactivated Polio Vaccine

IZB

Infectieziektebestrijding

LCILandelijke Coördinatie Infectieziektebestrijding (onderdeel RIVM)

Landelijke Coördinatie Infectieziektebestrijding (onderdeel van het RIVM)

MenC

Meningokokkenziekte type C

MenACWY

Meningokokkenziekte type ACWY

NCJ

Nederlands Centrum Jeugdgezondheid

NHGNederlands huisartsengenootschap

Nederlands Huisartsen Genootschap

NMS

Nederlandse Meningitis Stichting

NTvG

Nederlands Tijdschrift voor Geneeskunde

NVDA

Nederlandse Vereniging van Doktersassistenten

NVK

Nederlandse Vereniging voor Kindergeneeskunde

NVOG

Nederlandse Vereniging voor Obstetrie en Gynaecologie

OMT

Outbreak Management Team

Pneu

Pneumokokkenziekte

PSIE

Prenatale Screening Infectieziekten en Erytrocytenimmunisatie

RIVM

Rijksinstituut voor Volksgezondheid en Milieu

RSV (RS-virus)

Respiratoir Syncytieel virus

RVPRijksvaccinatieprogramma

Rijksvaccinatieprogramma

RMA

Regeling Medische Zorg Asielzoekers

TIG

Tetanusimmunoglobuline

V&VN

Verpleegkundigen & Verzorgenden Nederland

VNGVereniging van Nederlandse Gemeenten

Vereniging van Nederlandse Gemeenten

VWSMinisterie van Volksgezondheid, Welzijn en Sport

Ministerie van Volksgezondheid, Welzijn en Sport

WHO

World Health Organization

Wpg

Wet publieke gezondheid